Quadra
Allure MP
CRT-P with MultiPoint Pacing Cleared in Europe
St. Jude Medical‘s*Quadra
Allure MP, the world’s first*quadripolar cardiac resynchronization therapy pacemaker (CRT-P)
with the*MultiPoint
Pacing option, has been given the regulatory green light in Europe. The device uses the company’s Quartet LV cardiac leads equipped
with four electrodes to deliver electric signals to the heart.
MultiPoint
Pacing tech**logy allows different locations within the left side of the heart to be paced, providing more options for physicians to adjust resynchronization therapy to the individual patients’ functional anatomy. This has been confirmed in a recent study comparing the tech**logy to conventional*bi-ventricular
Pacing therapy which showed a 19 percent improvement in the response rate when using
MultiPoint Pacing. The improved ability to tailor cardiac
Pacing to each patient should prevent a good number of revision procedures that are often required when patients don’t sufficiently respond to pacemakers*after lead placement.
MultiPoint
Pacing is still considered investigational tech**logy by the FDA*and is therefore **t yet available in the U.S.
Flashback:*
St. Jude’s New Quadripolar CRT-P Coming to Europe…
Press release:
St. Jude Medical An**unces CE Mark Approval of the World’s Only MultiPoint Pacing Pacemaker…
Quadra Allure MP CRT-P with MultiPoint Pacing Cleared in Europe